BlackRock
PHAT icon

BlackRock’s Phathom Pharmaceuticals PHAT Stock Holding History

BlackRock’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.1M Buy
4,525,129
+463,133
+11% +$5.28M ﹤0.01% 2685
2026
Q1 		$45.1M Buy
4,061,996
+506,448
+14% +$6.4M ﹤0.01% 2577
2025
Q4 		$59M Buy
3,555,548
+153,224
+5% +$2.19M ﹤0.01% 2420
2025
Q3 		$40M Buy
3,402,324
+86,976
+3% +$898K ﹤0.01% 2639
2025
Q2 		$31.8M Sell
3,315,348
-8,255
-0.2% -$45.7K ﹤0.01% 2755
2025
Q1 		$20.8M Sell
3,323,603
-178,772
-5% -$1.09M ﹤0.01% 2914
2024
Q4 		$28.4M Buy
3,502,375
+379,805
+12% +$4.7M ﹤0.01% 2819
2024
Q3 		$56.5M Buy
3,122,570
+196,197
+7% +$2.74M ﹤0.01% 2402
2024
Q2 		$30.1M Buy
2,926,373
+180,993
+7% +$1.86M ﹤0.01% 2732
2024
Q1 		$29.2M Buy
2,745,380
+66,489
+2% +$565K ﹤0.01% 2774
2023
Q4 		$24.5M Buy
2,678,891
+241,149
+10% +$2.08M ﹤0.01% 2898
2023
Q3 		$25.3M Buy
2,437,742
+435,110
+22% +$5.97M ﹤0.01% 2804
2023
Q2 		$28.7M Buy
2,002,632
+369,722
+23% +$4.26M ﹤0.01% 2807
2023
Q1 		$11.7M Sell
1,632,910
-61,521
-4% -$540K ﹤0.01% 3237
2022
Q4 		$19M Buy
1,694,431
+151,281
+10% +$1.56M ﹤0.01% 3062
2022
Q3 		$17.1M Sell
1,543,150
-34,587
-2% -$330K ﹤0.01% 3121
2022
Q2 		$13.3M Buy
1,577,737
+199,220
+14% +$2.05M ﹤0.01% 3344
2022
Q1 		$18.8M Sell
1,378,517
-94,608
-6% -$1.53M ﹤0.01% 3209
2021
Q4 		$29M Buy
1,473,125
+290,247
+25% +$6.83M ﹤0.01% 3035
2021
Q3 		$38M Buy
1,182,878
+22,441
+2% +$746K ﹤0.01% 2845
2021
Q2 		$39.3M Buy
1,160,437
+344,497
+42% +$12.3M ﹤0.01% 2853
2021
Q1 		$30.6M Buy
815,940
+25,060
+3% +$1.05M ﹤0.01% 2936
2020
Q4 		$26.3M Buy
790,880
+73,968
+10% +$3M ﹤0.01% 2870
2020
Q3 		$26.3M Sell
716,912
-9,015
-1% -$312K ﹤0.01% 2704
2020
Q2 		$23.9M Buy
725,927
+140,981
+24% +$5.42M ﹤0.01% 2707
2020
Q1 		$15.1M Sell
584,946
-55,769
-9% -$1.86M ﹤0.01% 2758
2019
Q4 		$20M Buy
+640,715
New +$16.1M ﹤0.01% 2885

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

BlackRock's PHAT Position: Q2 2026 in Review

BlackRock increased its Phathom Pharmaceuticals (PHAT) stake by 11% in Q2 2026, buying an estimated $5.28M and bringing the position to 4,525,129 shares worth $49.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2685.

BlackRock first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $59M in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • BlackRock held 4,525,129 shares of Phathom Pharmaceuticals worth $49.1M as of Q2 2026.
  • BlackRock bought 463,133 Phathom Pharmaceuticals shares in Q2 2026, an estimated $5.28M.
  • Phathom Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2685 holding.
  • BlackRock first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • BlackRock's Phathom Pharmaceuticals position peaked at $59M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.